Home
HelpMayo Test ID HHV6V Human Herpesvirus-6, Molecular Detection, PCR, Spinal Fluid
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Container/Tube:
Preferred: Aliquot tube
Acceptable: Sterile vial
Specimen Volume: 0.5 mL
Collection Instructions: Collect specimen from second collection vial. Do not centrifuge.
Useful For
As an adjunct in the rapid diagnosis of human herpesvirus-6 infection using cerebrospinal fluid specimens
This test should not be used to screen asymptomatic patients.
Method Name
Real-Time Polymerase Chain Reaction (PCR)/DNA Probe Hybridization
Reporting Name
HHV-6 PCR, VariesSpecimen Type
CSFSpecimen Minimum Volume
0.3 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| CSF | Refrigerated (preferred) | 7 days | |
| Frozen | 7 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Human herpesvirus-6 (HHV-6) is a member of the Herpesviridae family. These viruses contain DNA surrounded by a lipid envelope. Among members of this group, this virus is most closely related to cytomegalovirus (CMV) and HHV-7. As with other members of the herpesvirus group (herpes simplex virus [HSV] 1, HSV 2, varicella-zoster virus, CMV, Epstein-Barr virus, HHV-7, HHV-8), HHV-6 may cause primary and reactivated infections subsequent to latent association with cells.(1) Infection with HHV-6 occurs early in childhood. Most adults (80%-90%) have been infected with this virus.
HHV-6 was first linked with exanthem subitum (roseola infantum) in 1998; since then, the virus has been associated with central nervous system disease almost exclusively in patients who are immunocompromised.(1) HHV-6 is commonly detected in patients posttransplantation. Clinical symptoms associated with this viral infection include febrile illness, pneumonitis, hepatitis, encephalitis, and bone marrow suppression. However, the majority of HHV-6 infections are asymptomatic.(2) The incidence of HHV-7 infection and its clinical manifestations posttransplantation are less well characterized.
HHV-6 is designated as variant A (HHV-6A) or variant B (HH6-B) depending on restriction enzyme digestion patterns and its reaction with monoclonal antibodies. Generally, variant B has been associated with exanthem subitum, whereas variant A has been found in many immunosuppressed patients.(3)
Reference Values
Negative
Cautions
The sensitivity of the assay is very dependent upon the quality of the specimen submitted.
A negative test does not exclude human herpesvirus-6 virus infection. Therefore, the results obtained should be used in conjunction with clinical findings to make an accurate diagnosis.
This assay detects nucleic acid and, therefore, cannot distinguish between viable and nonviable virus. Test performance depends on viral load in the specimen and may not correlate with cell culture performed on the same specimen.
Clinical Reference
1. Agut H, Bonnafous P, Gautheret-Dejean A: Laboratory and clinical aspects of human herpesvirus 6 infections. Clin Microbiol Rev. 2015 Apr:28(2):313-335
2. De Bolle L, Naesens L, De Clercq E: Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev. 2005 Jan;18(1):217-245
3. Dockrell DH, Paya CV: Human herpesvirus-6 and -7 in transplantation. Rev Med Virol. 2001 Jan-Feb;11(1):23-36
4. Abdel-Haq NM, Asmar BI: Human herpesvirus 6 (HHV6) infection. Indian J Pediatr. 2004 Jan;71(1):89-96
5. Dockrell DH, Smith TF, Paya CV: Human herpesvirus 6. Mayo Clin Proc. 1999 Feb;74(2):163-170
Method Description
Viral nucleic acid is extracted by the MagNA Pure automated instrument (Roche Applied Science) from clinical specimens. Primers directed to the immediate early gene of human herpesvirus-6 (HHV-6) produce a 195 base pairs amplicon. The LightCycler instrument (Roche Applied Science) amplifies and monitors the development of target nucleic acid sequences after the annealing step during polymerase chain reaction (PCR) cycling. This automated PCR system can rapidly (1 hour) detect amplicon development through stringent air-controlled temperature cycling and capillary cuvettes. The detection of amplified products is based on the fluorescence resonance energy transfer (FRET) principle. For FRET product detection, a hybridization probe with a donor fluorophore, fluorescein, on the 3'-end is excited by an external light source and emits light that is absorbed by a second hybridization probe with an acceptor fluorophore, LC-Red 640, at the 5'-end. The acceptor fluorophore then emits light of a different wavelength that can be measured with a signal that is proportional to the amount of specific PCR product. LightCycler hybridization probes are designed for exact homology to HHV-6.(Cockerill FR III, Uhl JR: Applications and challenges of real-time PCR for the clinical microbiology laboratory. In: Reischel U, Wittwer C, Cockerill F. Rapid Cycle Real-Time PCR - Methods and Applications. Springer-Verlag; 2002:3-30)
Day(s) Performed
Monday, Wednesday, Friday
Report Available
2 to 5 daysSpecimen Retention Time
1 weekPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87532
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| HHV6V | HHV-6 PCR, Varies | 33942-4 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| SS012 | Specimen Source | 31208-2 |
| 56092 | HHV-6 PCR, Varies | 33942-4 |
Interpretation
A positive result indicates the presence of specific DNA from human herpesvirus-6 (HHV-6) and supports the diagnosis of infection with this virus.
A negative result indicates the absence of detectable DNA from HHV-6 in the specimen, but it does not negate the presence of the virus or active or recent disease.